Current Trials
Pfizer C4771002 — Phase 3 C. difficile Vaccine (BEETHOVEN)
A randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of an investigational C. difficile vaccine.
Potential participants: Adults aged 65 years or older with qualifying risk factors for C. difficile infection. These may include recent hospitalizations, frequent healthcare visits, or qualifying antibiotic exposure. Additional medical and vaccination-history criteria apply.
AstraZeneca D7960C00015 — Phase 3 Cardiovascular (AZURE-Outcomes)
A randomized, double-blind, placebo-controlled study evaluating the investigational oral PCSK9 inhibitor AZD0780 for reducing major cardiovascular events.
Group 1 — Established cardiovascular disease: Adults aged 18 years or older with a qualifying history of myocardial infarction, ischemic stroke, or lower-limb revascularization for symptomatic peripheral artery disease. LDL cholesterol requirements and additional risk factors depend on medical history and the timing of cardiovascular events.
Group 2 — Increased cardiovascular risk: Men aged 50 years or older and women aged 55 years or older without specified prior ASCVD events, with LDL-C of at least 100 mg/dL and qualifying evidence of atherosclerosis or high-risk diabetes. Additional risk factors may be required.
Participants must also meet the study’s background lipid-lowering treatment and other eligibility requirements.
AstraZeneca D7261C00003 — Phase 3 Type 2 Diabetes (Eluminate-5)
A randomized, double-blind study evaluating elecoglipron combined with dapagliflozin compared with either medication alone in adults with type 2 diabetes.
Potential participants: Adults aged 18 years or older with type 2 diabetes diagnosed at least 90 days before screening, HbA1c between 7.0% and 10.5%, and BMI of at least 23 kg/m².
Participants may qualify with diabetes managed by lifestyle measures or qualifying stable background glucose-lowering treatment. Stable body weight and additional medical criteria apply.
AstraZeneca D7265C00001 — Phase 3 Chronic Kidney Disease (Elevate-CKD)
A randomized, double-blind, placebo-controlled study evaluating whether elecoglipron improves kidney-related outcomes in adults with chronic kidney disease.
Potential participants: Adults aged 18 years or older with confirmed chronic kidney disease, with or without type 2 diabetes.
Participants must meet qualifying kidney-function and urine albumin measurements, including UACR of at least 30 mg/g and eGFR of at least 20 mL/min/1.73 m² within study-defined ranges. Background kidney-protective treatment and other medical eligibility requirements apply.
AstraZeneca D8750C00014 — Phase 3 Obesity / Overweight (SELENE 1)
A randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of investigational AZD6234 for weight management.
Potential participants: Adults aged 18 years or older without type 2 diabetes who have:
- BMI of at least 30 kg/m²; OR
- BMI of at least 27 kg/m² with at least one qualifying weight-related medical condition, such as hypertension, high cholesterol, sleep apnea, cardiovascular disease, chronic kidney disease, or knee osteoarthritis.
Participants must have maintained relatively stable weight for at least three months and have a history of at least one unsuccessful weight-loss attempt. Additional criteria apply.
Trial descriptions are provided for general informational purposes. Participation is subject to full screening and eligibility confirmation by the research team.
General information
- Treatment Research generally involves an intervention such as medication, psychotherapy, new devices, or new approaches to surgery or radiation therapy.
- Prevention Research looks for better ways to prevent disorders from developing or returning. Different kinds of prevention research may study medicines, vitamins, vaccines, minerals, or lifestyle changes.
- Diagnostic Research refers to the practice of looking for better ways to identify a particular disorder or condition.
- Screening Research aims to find the best ways to detect certain disorders or health conditions.
Phases of clinical trials:
When clinical research is used to evaluate medications and devices clinical trials are a kind of clinical research designed to evaluate and test new interventions such as psychotherapy or medications. Clinical trials are often conducted in four phases. The trials at each phase have a different purpose and help scientists answer different questions.
- Phase I trials
Researchers test an experimental drug or treatment in a small group of people for the first time. The researchers evaluate the treatment’s safety, determine a safe dosage range, and identify side effects. - Phase II trials
The experimental drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety. - Phase III trials
The experimental study drug or treatment is given to large groups of people. Researchers confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely. - Phase IV trials
Post-marketing studies, which are conducted after a treatment is approved for use by the FDA, provide additional information including the treatment or drug’s risks, benefits, and best use.
Contact us to inquire about becoming a participant in one of our clinical trials.